Effects of Ethyl Benzoate on Performance, Morphology, and Erosion of PLGA Implants Formed In Situ

被引:19
作者
Astaneh, R. [1 ]
Erfan, M. [1 ,2 ]
Barzin, J. [3 ]
Mobedi, H. [4 ]
Moghimi, Hr. [2 ]
机构
[1] Shahid Beheshti Univ Med Sci, Sch Med, Dept Biomed Engn & Med Phys, Tehran, Iran
[2] Shahid Beheshti Univ Med Sci, Sch Pharm, Dept Pharmaceut, Tehran, Iran
[3] Iran Polymer & Petrochem Inst, Dept Biomat, Tehran, Iran
[4] Iran Polymer & Petrochem Inst, Dept Novel Drug Delivery, Tehran, Iran
关键词
Drug release; Erosion; In situ forming implant; Morphology; PLGA;
D O I
10.1002/adv.20114
中图分类号
TQ [化学工业];
学科分类号
0817 ;
摘要
An in Situ forming implant (ISFI) is a novel drug delivery system used for protein and peptide delivery, especially for cancer treatment. An ISFI based on 33% (w/w) poly(D,L-lactide-co-glycolide)(PLGA; 50:50)/3% (w/w) leuprolide acetate (LA)/64% (w/w) N-methyl-2-pyrrolidone (NMP) was prepared for this study. After injection of the final formulation, which is a viscous liquid to an aqueous medium, it deforms to become a semisolid or solid matrix. The performance of this matrix was investigated on the basis of peptide release from it. Erosion and morphology of ISFI were also Studied. The effects of adding 12.89% (w/w) ethyl benzoate (EB) as a rate-modifying agent on performance, erosion, and morphology of ISFI were assessed. The implant containing EB showed very low burst release (5.53% +/- 0.829%) and the morphology turns to closed pore-like structures. After adding EB, the morphology turns to closed pore-like structures. This type of morphology has very close relation to the performance of the implant as well. Finally, the effect of EB on performance, erosion, and morphology is explained by means of solvent-nonsolvent affinity, water permeation, and the rate of phase inversion. (C) 2008 Wiley Periodicals, Inc. Adv Polym Techn 27:17-26, 2008; Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/adv.20114
引用
收藏
页码:17 / 26
页数:10
相关论文
共 40 条
[1]  
[Anonymous], [No title captured]
[2]  
Astaneh Reyhaneh, 2006, DARU-Journal of Pharmaceutical Sciences, V14, P65
[3]  
Barton BF, 1997, J POLYM SCI POL PHYS, V35, P569, DOI 10.1002/(SICI)1099-0488(199703)35:4<569::AID-POLB5>3.0.CO
[4]  
2-L
[5]  
Barzin J, 2005, IRAN POLYM J, V14, P353
[6]   Characterization of polyethersulfone hemodialysis membrane by ultrafiltration and atomic force microscopy [J].
Barzin, J ;
Feng, C ;
Khulbe, KC ;
Matsuura, T ;
Madaeni, SS ;
Mirzadeh, H .
JOURNAL OF MEMBRANE SCIENCE, 2004, 237 (1-2) :77-85
[7]   Effect of polyvinylpyrrolidone on morphology and performance of hemodialysis membranes prepared from polyether sulfone [J].
Barzin, J ;
Madaeni, SS ;
Mirzadeh, H ;
Mehrabzadeh, M .
JOURNAL OF APPLIED POLYMER SCIENCE, 2004, 92 (06) :3804-3813
[8]   Phase inversion dynamics of PLGA solutions related to drug delivery - Part II. The role of solution thermodynamics and bath-side mass transfer [J].
Brodbeck, KJ ;
DesNoyer, JR ;
McHugh, AJ .
JOURNAL OF CONTROLLED RELEASE, 1999, 62 (03) :333-344
[9]  
BRODBECK KJ, 2000, Patent No. 6130200
[10]   Beyond Estrogen: Targeting Gonadotropin Hormones in the Treatment of Alzheimer's Disease [J].
Casadesus, Gemma ;
Zhu, Xiongwei ;
Atwood, Craig S. ;
Webber, Kate M. ;
Perry, George ;
Bowen, Richard L. ;
Smith, Mark A. .
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2004, 3 (04) :281-285